Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

This publication has 46 references indexed in Scilit:

• Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry
  The Journal of Pathology, 2005
• REporting recommendations for tumour MARKer prognostic studies (REMARK)
  British Journal of Cancer, 2005
• Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in theTP53gene on survival in patients with advanced ovarian carcinoma
  Human Mutation, 2004
• Critical evaluation of p53 as a prognostic marker in ovarian cancer
  Expert Reviews in Molecular Medicine, 2004
• Distinct subtypes of serous ovarian carcinoma identified by p53 determination☆
  Gynecologic Oncology, 2003
• Cisplatin: mode of cytotoxic action and molecular basis of resistance
  Oncogene, 2003
• Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin
  Cancer Letters, 2003
• Tissue microarrays for high-throughput molecular profiling of tumor specimens
  Nature Medicine, 1998
• The significance of p53 mutation and over-expression in ovarian cancer prognosis
  International Journal of Gynecologic Cancer, 1996
• ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation
  Cell, 1992